This is demonstrated by Best et al.’s[134] study using the GALAD (Gender, Age, AFP-L3, and Des-carboxy-prothormbin) score to predict early detection of NAFLD-associated HCC cases in Europe and Japan, including the sub-group of patients without cirrhosis. The gene discussed is AFP; the disease is metabolic dysfunction-associated steatotic liver disease.